{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:29:45Z","timestamp":1783924185794,"version":"3.55.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and the world; with no Food and Drug Administration\u2013approved pharmacological treatment available, it remains an area of unmet medical need. In nonalcoholic steatohepatitis (NASH), the most important predictor of clinical outcome is the fibrosis stage. Moreover, the Food and Drug Administration recommends that clinical trials for drugs to treat this disease include patients with fibrosis stage 2 or greater. Therefore, when using animal models for investigating the pathophysiology of NAFLD and for the preclinical evaluation of new drugs, it is important that the animals develop substantial fibrosis. The aim of this study was to develop a mouse model of NAFLD that replicated the disease in humans, including obesity and progressive liver fibrosis. Agouti yellow mutant mice, which have hyperphagia, were fed a Western diet and water containing high\u2010fructose corn syrup for 16\u2009weeks. Mice became obese and developed glucose intolerance. Their gut microbiota showed dysbiosis with changes that replicate some of the changes described in humans with NASH. They developed NASH with activity scores of 5\u20136 and fibrosis, which was stage 1 after 16\u2009weeks, and stage 3 after 12\u2009months. Changes in liver gene expression assessed by gene\u2010set enrichment analysis showed 90% similarity with changes in human patients with NASH. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Ay mice, when fed a Western diet similar to that consumed by humans, develop obesity and NASH with liver histology, including fibrosis, and gene expression changes that are highly similar to the disease in humans.<\/jats:p>","DOI":"10.1002\/hep4.2035","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:40:57Z","timestamp":1659591657000},"page":"2676-2688","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3"],"prefix":"10.1097","volume":"6","author":[{"given":"Kristy","family":"St. Rose","sequence":"first","affiliation":[{"name":"Department of Health and Nutrition Sciences,Brooklyn College,CUNY,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medicine,Columbia University,New York,New York,USA"},{"name":"Department of Forensic Medicine,Medical College of Nantong University,Nantong,Jiangsu,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-2133","authenticated-orcid":false,"given":"Fangxi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathobiology,New York University College of Dentistry,New York,New York,USA"},{"name":"Department of Surgery,New York University School of Medicine,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition Sciences,Brooklyn College,CUNY,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Dweck","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition Sciences,Brooklyn College,CUNY,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathobiology,New York University College of Dentistry,New York,New York,USA"},{"name":"Department of Surgery,New York University School of Medicine,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Schwabe","sequence":"additional","affiliation":[{"name":"Department of Medicine,Columbia University,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-6459","authenticated-orcid":false,"given":"Jorge Matias","family":"Caviglia","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition Sciences,Brooklyn College,CUNY,New York,New York,USA"},{"name":"Department of Medicine,Columbia University,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"hep42035-bib-0001-20241127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep42035-bib-0002-20241127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2001-12925","article-title":"Nonalcoholic steatohepatitis: definition and pathology","volume":"21","year":"2001","journal-title":"Semin Liver Dis"},{"key":"hep42035-bib-0003-20241127","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep42035-bib-0004-20241127","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep42035-bib-0005-20241127","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo\u2010controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"hep42035-bib-0006-20241127","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"hep42035-bib-0007-20241127","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non\u2010cirrhotic, non\u2010alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo\u2010controlled trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep42035-bib-0009-20241127","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.31897","article-title":"A systematic review of animal models of NAFLD finds high\u2010fat, high\u2010fructose diets most closely resemble human NAFLD","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep42035-bib-0010-20241127","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non\u2010alcoholic fatty liver disease","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep42035-bib-0011-20241127","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10620-015-3977-1","article-title":"Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"hep42035-bib-0012-20241127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep42035-bib-0013-20241127","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep42035-bib-0014-20241127","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep42035-bib-0015-20241127","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause\u2010specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi\u2010national cohort study","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep42035-bib-0016-20241127","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta\u2010analysis","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"hep42035-bib-0018-20241127","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep42035-bib-0019-20241127","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1194\/jlr.D700017-JLR200","article-title":"A simple and rapid method to assay triacylglycerol in cells and tissues","volume":"48","year":"2007","journal-title":"J Lipid Res"},{"key":"hep42035-bib-0020-20241127","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.29627","article-title":"MicroRNA\u201021 and dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep42035-bib-0021-20241127","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1242\/dmm.003467","article-title":"Mouse models of the metabolic syndrome","volume":"3","year":"2010","journal-title":"Dis Model Mech"},{"key":"hep42035-bib-0022-20241127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hepres.2006.07.009","article-title":"Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK\u2010A(y) mice","volume":"36","year":"2006","journal-title":"Hepatol Res"},{"key":"hep42035-bib-0023-20241127","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.peptides.2005.03.064","article-title":"Obesity\u2010associated mutations in the human melanocortin\u20104 receptor gene","volume":"27","year":"2006","journal-title":"Peptides"},{"key":"hep42035-bib-0024-20241127","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2011.01.033","article-title":"The genetic epidemiology of melanocortin 4 receptor variants","volume":"660","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"hep42035-bib-0025-20241127","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/hep.23797","article-title":"High\u2010fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep42035-bib-0026-20241127","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1152\/ajpgi.00145.2011","article-title":"Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition","volume":"301","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"hep42035-bib-0027-20241127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/advances\/nmy002","article-title":"Modeling the western diet for preclinical investigations","volume":"9","year":"2018","journal-title":"Adv Nutr"},{"key":"hep42035-bib-0028-20241127","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"hep42035-bib-0029-20241127","article-title":"Pathology of fatty liver disease","volume":"20","year":"2007","journal-title":"Mod Pathol"},{"key":"hep42035-bib-0030-20241127","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2007.05.012","article-title":"Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction","volume":"133","year":"2007","journal-title":"Gastroenterology"},{"key":"hep42035-bib-0031-20241127","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","year":"2008","journal-title":"Physiol Rev"},{"key":"hep42035-bib-0032-20241127","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer\u2010associated fibroblast subpopulations","volume":"39","year":"2021","journal-title":"Cancer Cell"},{"key":"hep42035-bib-0033-20241127","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep42035-bib-0034-20241127","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome\u2010based metagenomic signature for non\u2010invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","year":"2017","journal-title":"Cell Metab"},{"key":"hep42035-bib-0035-20241127","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"hep42035-bib-0036-20241127","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep42035-bib-0037-20241127","article-title":"Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"hep42035-bib-0038-20241127","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","article-title":"Melanocortin 4 receptor\u2010deficient mice as a novel mouse model of nonalcoholic steatohepatitis","volume":"179","year":"2011","journal-title":"Am J Pathol"},{"key":"hep42035-bib-0039-20241127","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet\u2010induced animal model of non\u2010alcoholic fatty liver disease and hepatocellular cancer","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep42035-bib-0040-20241127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet\u2010 and chemical\u2010induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep42035-bib-0041-20241127","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.chom.2017.10.005","article-title":"The human microbiome and obesity: moving beyond associations","volume":"22","year":"2017","journal-title":"Cell Host Microbe"},{"key":"hep42035-bib-0042-20241127","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep42035-bib-0043-20241127","article-title":"Gut microbiota dysbiosis in patients with biopsy\u2010proven nonalcoholic fatty liver disease: a cross\u2010sectional study in Taiwan","volume":"12","year":"2020","journal-title":"Nutrients"},{"key":"hep42035-bib-0044-20241127","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2018.05.002","article-title":"Towards a definite mouse model of NAFLD","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep42035-bib-0045-20241127","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","year":"2002","journal-title":"J Hepatol"},{"key":"hep42035-bib-0046-20241127","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1073\/pnas.92.11.4728","article-title":"Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur","volume":"92","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep42035-bib-0047-20241127","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nm.4346","article-title":"Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex\u2010independent disease modeling","volume":"23","year":"2017","journal-title":"Nat Med"},{"key":"hep42035-bib-0048-20241127","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF\u2010beta signaling and hepatic fibrosis","volume":"13","year":"2007","journal-title":"Nat Med"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:14:17Z","timestamp":1732709657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2035","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"2021-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}